| NCT ID | NCT06958341 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Charite University, Berlin, Germany |
| Condition | Encephalopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2021-02-01 |
| Primary Completion | 2031-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2021-02-01 with a primary completion date of 2031-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A variety of antineuronal antibodies have been detected in the cerebrospinal fluid (CSF) of patients with neurological diseases. This raises the question of whether these antibodies are disease-specific or merely an epiphenomenon of inflammatory processes in the brain. The registry was established with the following objectives: \[1\] Are antineuronal antibodies much more common than previously thought in various neurological disorders for which the etiology has not yet been elucidated? \[2\] Can further correlations, such as those between HSV infection and NMDA receptor autoimmunity, be identified? \[3\] Are these antibodies mainly non-specific epiphenomena or are they crucial for the pathogenesis? \[4\] What is the clinical course of patients with antineuronal antibodies and their response to therapy? These questions will be addressed in a broad immunohistological screening of a large number of CSF samples and a clinical database of patients with neurological disorders.
Eligibility Criteria
Inclusion Criteria: 1. Differential diagnosis: suspected neuroimmunological disease in which a lumbar puncture is indicated for further diagnosis and treatment decision 2. Individuals with unclear clinical diagnosis where additional CSF is to be collected for isolation of B cells and production of monoclonal antibodies. The clinical condition of the patients and his/her compliance have to allow an extra 2-3 ml of CSF to be collected. 3. Age: all age groups 4. Gender: patients of both sexes will be included Exclusion criteria: \[1\] Withdrawal of consent
Contact & Investigator
Marc Nikolaus, MD
PRINCIPAL INVESTIGATOR
Charite - Universitaetsmedizin Berlin
Frequently Asked Questions
Who can join the NCT06958341 clinical trial?
This trial is open to participants of all sexes, studying Encephalopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06958341 currently recruiting?
Yes, NCT06958341 is actively recruiting participants. Contact the research team at markus.schuelke@charite.de for enrollment information.
Where is the NCT06958341 trial being conducted?
This trial is being conducted at Berlin, Germany, Ulm, Germany.
Who is sponsoring the NCT06958341 clinical trial?
NCT06958341 is sponsored by Charite University, Berlin, Germany. The principal investigator is Marc Nikolaus, MD at Charite - Universitaetsmedizin Berlin. The trial plans to enroll 300 participants.